Cutler Group’s Health Catalyst HCAT Stock Holding History

Cutler Group’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-112	Closed	-$1K	–	4172
2022 Q4	$1K	Sell	112 -2,294	-95%	-$22.1K	﹤0.01%	4023
2022 Q3	$23K	Buy	+2,406	New	+$31.9K	﹤0.01%	2504

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Cutler Group's HCAT Position: Q1 2023 in Review

Cutler Group sold out of Health Catalyst (HCAT) in Q1 2023, closing a stake of 112 shares — an estimated $1K sold.

Cutler Group first reported a position in HCAT in Q3 2022 and held it in 2 quarters. The position peaked at $23K in Q3 2022. 161 funds tracked by Wall St. Rank hold HCAT as of Q1 2023.

Cutler Group reported no remaining Health Catalyst position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 112 Health Catalyst shares in Q1 2023, an estimated $1K.
Cutler Group first reported a position in Health Catalyst in Q3 2022 and held it in 2 quarters.
Cutler Group's Health Catalyst position peaked at $23K in Q3 2022.
161 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.